eligibility_summary
Adults 18–70 with R/R indolent B‑cell lymphoma or DLBCL after ≥2 regimens (CD20 and anthracycline), post‑HSCT relapse/ineligible or double/triple‑hit, CD19+, measurable disease, ECOG 0–1, survival >12 wks, adequate blood counts/organ function, SaO2>91%, LVEF ≥45%. Washouts: prior CD19 CAR‑T ≥1 mo, steroids 2 wks, immunosuppressants 4 wks, other therapy 2 wks. AEs ≤grade1, contraception 12 mo. Exclude non‑LL CNS disease, recent chemo/trial, active HBV/HCV, HIV/syphilis, infection, major cardiac/thrombotic events, pregnancy, QT prolongation, ADA+.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Meta10-19, a metabolically armed CD19 CAR‑T cell therapy (autologous, gene‑modified T cells). Mechanism: T cells engineered with a CAR recognize CD19 on B cells, activating cytotoxic killing and cytokine release, added “metabolic armoring” is intended to enhance T‑cell metabolic fitness, persistence, and function in suppressive tumor microenvironments (specific construct not disclosed). Regimen includes cyclophosphamide (alkylating agent) and fludarabine (purine analog) for lymphodepletion to promote CAR‑T expansion. Targets: CD19+ malignant B cells, effector cells: patient T cells. Pathways: CAR signaling (CD3ζ/costimulation) and T‑cell metabolic programs, lymphodepletion reduces host lymphocytes. Population: r/r B‑cell NHL. Phase: Early Phase 1, outcomes: safety, efficacy, PK/PD.